BCRX AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.
BCRX Current Performance
3.97%
Biocryst pharmaceuticals inc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to BCRX
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
PRME | Prime medicine inc | - | 2 | 4 | 2 | 1 | |
ALEC | Alector inc | 3 | 3 | 3 | 2 | 1 | |
BLUE | Bluebird bio inc | 4 | 3 | 2 | 1 | 1 | |
BEAM | Beam therapeutics inc | 2 | 4 | 4 | 3 | 1 | |
SNDX | Syndax pharmaceuticals inc | 2 | 4 | 4 | 3 | 1 |
- PRME Prime medicine incValue -Trend 2Swing Trading 4Whale Interest 2Dividend 1See more
BCRX Profile
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.